NRAS and melanoma: The efficacy of the combination of MEKi (binimetinib/MEK162) and CDK4/6 inhibitors is currently also assessed in patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) (palbociclib, NCT03170206)—and will be followed up on in NRAS-mutant melanoma based on promising phase Ib trial results (ribociclib, NCT01781572).